Tissue Factor Pathway Inhibitor (TFPI) and Haemorrhagic Manifestations in Haemophilia A and B Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

164 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-02-29

Study Completion Date

2016-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Haemophilia is a rare and serious congenital defect of blood coagulation due to a genetic mutation on a sexual chromosome. It affects quasi-essentially the men and it is responsible for bleeding. There are two types of haemophilia: Haemophilia A, (85 % of cases), due to a factor VIII (FVIII) deficiency and Haemophilia B (15 % of cases) due to factor IX (FIX) deficiency. According to the intensity of the defect, there are three forms of haemophilia: severe (FVIII or FIX lower than 1 %), moderate (factor level between 1 and 5 %), minor (factor level between 5 and 40 %). For a same level of factor VIII or IX, hemorrhagic manifestations are variable from one patient to the other. Moreover, several studies showed that haemophilic B patients bleed less and consume fewer anti-hemophilic concentrate that haemophilic A patients.

The main inhibitors of the coagulation are antithrombin, Protein C-Protein S-Thrombomodulin system, and tissue factor pathway inhibitor (TFPI). TFPI is the specific and exclusive inhibitor of tissue factor pathway that is the main way by which plasmatic coagulation starts. TFPI is a potent direct inhibitor of factor Xa and Xa-dependent inhibitor of the VIIa-Tissue Factor (TF) complex. In hemophilic patient, the production of Xa by the amplification pathway being strongly altered because of factor VIII or IX deficiency, thrombin generation (via Xa) comes exclusively from TFPI regulated tissue factor pathway. We can thus say that if haemophilic patients bleed, it is also because of the presence of TFPI that inhibits at the same time Xa and the complex TF-VIIa as soon as factor Xa is generated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

TFPI Levels in Haemophilia A and B Patients

NCT04570696

Haemophilia A and B

UNKNOWN

Study Evaluating Inhibitor Specificity in Hemophilia A

NCT00151385

Hemophilia A

WITHDRAWN PHASE4

Use of a TGA and TEM in the Assessment of the Efficacy of Treatment With APCC or rFVIIa

NCT01856751

Haemophilia

UNKNOWN

Hemophilia Inhibitor Previously Untreated Patient Study

NCT01652027

Hemophilia A

COMPLETED

Thrombin Generation Numerical Models Validation in Haemophilic Case

NCT02300519

Haemophilia B Haemophilia A

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemophilia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

haemophilia A

1. Blood specimen for measuring :

* Free TFPI and TFPI activity levels
* Thrombin generation in platelet rich plasma (PRP) and platelet poor plasma (PPP)
* Thrombin generation assay (TGA) in fresh PRP and frozen PPP
2. Hemorrhage score for each patient

blood specimen

Intervention Type OTHER

Haemophilia B

1. Blood specimen for measuring :

* Free TFPI and TFPI activity levels
* Thrombin generation in platelet rich plasma (PRP) and platelet poor plasma (PPP)
* Thrombin generation assay (TGA) in fresh PRP and frozen PPP
2. Hemorrhage score for each patient

blood specimen

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood specimen

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Haemophilia A and B patients between 18 and 65 years old, whatever the severity of their disease, who have signed the informed consent form
* On-demand or on prophylactic therapy.
* Regular monitoring in investigator center.

Exclusion Criteria

* \- Haemophilia patients under 18.
* Presence of an inhibitor at any time before or during the study period.
* Patients who received factor VIII concentrate less than 72 hours or factor IX concentrate less than 96 hours before blood collection
* Patients who refused to sign informed consent
* Patient data over the last 5 years at least not available.
* No regular monitoring in haemophilia center (required at least one visit every 18 months for severe or moderate hemophiliac patients).

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No